author-photo

Hui Jung Sin

3

Papers

48

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (41)
THU0185 Safety, Pharmacokinetics and Proof-of-mechanism of an Oral Bruton's Tyrosine Kinase Inhibitor HM71224 in Healthy Adult Volunteers

2015 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (4)
THU0150 Safety, Pharmacokinetics, Pharmacodynamics, and Food Effect of an Oral Bruton's Tyrosine Kinase Inhibitor HM71224 in Healthy Subjects

2014 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (3)